Centre for Cardiovascular Genetics, BHF Laboratories, The Rayne Building, Department of Medicine, Royal Free and University College Medical School, 5 University Street, London, United Kingdom.
Mol Med. 2010 Sep-Oct;16(9-10):389-99. doi: 10.2119/molmed.2010.00044. Epub 2010 May 20.
The role of common APOE variants on plasma lipids, particularly low density lipoprotein (LDL) levels, and coronary heart disease (CHD) risk is well known; the influence of variation in the other nearby apolipoprotein genes APOC1, APOC4 and APOC2 is unclear. This study examines the association between APOE/C1/C4/C2 gene cluster variation using tagging SNPs and plasma lipid concentration along with risk of CHD in a prospective cohort. Genotypes for 11 common APOE/C1/C4/C2 SNPs were determined in 2,767 middle-aged (49 to 64 years) men from the Second Northwick Park Heart Study, with 275 CHD events over a 15-year follow-up period. Seven SNPs showed significant associations with one or more lipid trait in univariate analysis. Multivariate and haplotype analysis showed that the APOE genotypes are most strongly associated with effects on LDL-C and apoB concentration (explaining 3.4% of the LDL-C variance) while the other SNPs in this gene cluster explained an additional 1.2%. Haplotypes in APOC2 and APOC4 were associated with modest effects on HDL-C and apoAI (explaining respectively 1.4% and 1.2%). Carriers of the APOE ɛ2 SNP had a significantly lower risk of CHD hazard ratio (HR) of 0.63 (95% confidence interval [CI]: 0.42-0.95), as did carriers of the APOC2 SNP rs5127 (HR = 0.72, 95% CI: 0.56-0.93), while carriers of APOC1 SNP rs4803770 had higher risk of CHD (HR = 1.36, 95% CI: 1.04-1.78) compared with noncarriers. While the common APOE polymorphism explains the majority of the locus genetic determinants of plasma lipid levels, additional SNPs in the APOC1/C2 region may contribute to CHD risk, but these effects require confirmation.
载脂蛋白 E (APOE)常见变体对血浆脂质(尤其是低密度脂蛋白 [LDL] 水平)和冠心病(CHD)风险的影响是众所周知的;而其他附近载脂蛋白基因 APOC1、APOC4 和 APOC2 变异的影响尚不清楚。本研究使用标记 SNP 检查了 APOE/C1/C4/C2 基因簇变异与前瞻性队列中血浆脂质浓度和 CHD 风险之间的关联。在为期 15 年的随访中,在第二次北威克公园心脏研究(Second Northwick Park Heart Study)的 2767 名中年(49 至 64 岁)男性中确定了 11 种常见 APOE/C1/C4/C2 SNP 的基因型,有 275 例 CHD 事件。单变量分析显示,7 种 SNP 与一种或多种脂质特征显著相关。多变量和单倍型分析表明,APOE 基因型与 LDL-C 和 apoB 浓度的影响最为密切相关(解释 LDL-C 变异的 3.4%),而该基因簇中的其他 SNP 则额外解释了 1.2%。APOC2 和 APOC4 中的单倍型与 HDL-C 和 apoAI 的适度影响相关(分别解释 1.4%和 1.2%)。APOE ɛ2 SNP 的携带者患 CHD 的风险显著降低(危险比 [HR]为 0.63,95%置信区间 [CI]:0.42-0.95),APOC2 SNP rs5127 的携带者(HR = 0.72,95% CI:0.56-0.93)也是如此,而 APOC1 SNP rs4803770 的携带者患 CHD 的风险更高(HR = 1.36,95% CI:1.04-1.78)与非携带者相比。虽然常见的 APOE 多态性解释了该基因座血浆脂质水平的大多数遗传决定因素,但 APOC1/C2 区域的其他 SNP 可能与 CHD 风险有关,但这些影响需要进一步证实。